Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Missouri for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Missouri only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Missouri (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Stephen Sides (NPI 1366428914)

Field	Value
Entity Type	Individual
Organization	Stephen Sides
Address	1241 W Stadium Blvd
City	Jefferson City
State	MO
ZIP	65109
Taxonomy	Rheumatology Physician
NPI Enumerated	December 15, 2005

Payer Source	Total Paid
Medicare	$2.9M
Medicaid	$0

Key Findings

The provider’s Medicare billing is dominated by infused and injected biologic therapies: high-revenue HCPCS codes include J3380 (vedolizumab), J0897 (denosumab), J2350 (ocrelizumab), J0129 (abatacept) and J1602 (golimumab), which together reflect an operational model oriented around in-office drug administration rather than primary care clinic visits. This code mix is consistent with a specialty rheumatology practice that delivers and bills for parenteral biologic treatments and related infusion services.

Revenue concentration is high: the precomputed top 3 Medicare codes by revenue account for 55.0% of this provider’s total Medicare revenue, with J3380 reported at $627.3K (21.5% of total Medicare revenue), J0897 at $551.9K (18.9%), and J2350 at $423.3K (14.5%). This degree of concentration indicates that a relatively small set of biologic drug codes is driving the majority of Medicare receipts.

This provider is effectively single-payer in scale: total Medicare revenue is $2.9M while there is no Medicaid billing on file, so the practice’s reimbursement exposure and contracting leverage will be driven almost entirely by Medicare payment rates and utilization patterns. The absence of Medicaid activity suggests a payer mix skewed to Medicare beneficiaries and possibly commercial patients not visible in this data extract.

On competitive standing, several individual codes show markedly elevated national positions: J0897 ranks #96 of 10057 providers nationally (99th percentile) and is labeled an "extreme outlier," indicating extraordinarily high denosumab volume compared with peers. J3380 ranks #19 of 620 providers (97th percentile) and is described as "notably above typical national volume," while J2350 is a more typical contributor (ranks #76 of 105, 28th percentile). These mixed signals show dominance on some specific biologics but ordinary participation on others.

Operational throughput is supported by high-volume infusion/administration and related E/M codes: 96365 (initial IV infusion) is reported with strong relative volume (rank #217 of 8873, 98th percentile) and 96372 (therapeutic injection) is an extreme outlier (rank #666 of 58224, 99th percentile), while 99214 office visits also rank notably high (94th percentile). Together these patterns point to a high-throughput infusion suite and routine billing for both drug administration and moderate-complexity outpatient visits.

Several codes combine modest average payments per unit with very high claim counts—J3380 shows an average paid/claim of $17 with 36.9K claims and J0897 shows $18 average paid/claim with 30.7K claims—meaning volume, not per-unit price, is the dominant driver of revenue for those lines. The rankings and descriptor labels highlight that this provider’s scale for specific injectable drugs is well above typical national practice, which has implications for inventory management, infusion capacity, and payer negotiations.

The provider has a long-tenure NPI (enumerated 2005-12-15, ~21 years ago) and is taxonomy-coded as a Rheumatology Physician, which aligns with the observed biologic and infusion-focused billing profile; this longevity supports an established referral and treatment pattern for chronic autoimmune conditions requiring parenteral biologic therapy. The practice’s clinical specialization likely drives both patient mix and the concentration in high-volume biologic codes.

Absence of Medicaid billing on file combined with concentrated Medicare revenues suggests limited engagement with the Medicaid population or contractual non-participation in state Medicaid programs. For payers and network analysts, that lack of Medicaid activity is an important business signal when assessing coverage, network adequacy, and opportunities for Medicaid partnerships or credentialing outreach.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

45 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J3380	Injection, vedolizumab, intravenous, 1 mg	36,900	$20	$627.3K
J0897	Injection, denosumab, 1 mg	30,660	$20	$551.9K
J2350	Injection, ocrelizumab, 1 mg	9,010	$50	$423.3K
J0129	Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	11,550	$30	$392.7K
J1602	Injection, golimumab, 1 mg, for intravenous use	34,800	$10	$382.8K
J9312	Injection, rituximab, 10 mg	3,350	$60	$211.2K
J1745	Injection, infliximab, excludes biosimilar, 10 mg	6,190	$30	$160.9K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	650	$80	$52.7K
96365	The provider administers the initial intravenous infusion of a medication or other substance for a period up to one hour to prevent, treat, or diagnose a condition or disease.	670	$50	$30.3K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	210	$90	$19.2K

Showing 1–10 of 45

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 45 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Missouri Distribution

Stephen Sides — 7 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Missouri

Full comparison — all codes billed, vs. state median

45 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J0129	9	20	10,880	$30	$443.6K
J2350	1	10	9,010	$50	$424.2K
J9312	5	10	3,350	$60	$315.8K
J3380	2	20	10,800	$20	$280.1K
J1602	5	20	13,150	$10	$266.8K
J1745	8	40	3,060	$30	$118.1K
J0897	3	210	2,400	$20	$82.4K
96413	53	160	140	$100	$19.1K
99214	376	8,960	100	$80	$13.9K
99213	2,171	8,730	70	$50	$7K

Showing 1–10 of 45

Related Providers

Other providers that share a Tax Identification Number (TIN) with Stephen Sides, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Shadi Haddadin	MO	Hematology & Oncology Physician	$2.2M	$0
Tamara Hopkins	MO	Hematology & Oncology Physician	$887.1K	$0
Thomas Schneider	MO	Pulmonary Disease Physician	$411.2K	$0
Michael Snyder	MO	Orthopaedic Surgery Physician	$320.1K	$0
Jonathan Craighead	MO	Orthopaedic Surgery Physician	$259.6K	$0
Philip Rumbaoa	MO	Phlebology Physician	$257.7K	$0
Stephanie Hose	MO	Dermatology Physician	$222.7K	$0
Indumathi Baskar	MO	Internal Medicine Physician	$218.4K	$0
Philip Wilson	MO	Ophthalmology Physician	$206.1K	$0
Steve Linsenbardt	MO	Internal Medicine Physician	$204.4K	$0

Nearby Providers

Other providers in the same ZIP code as Stephen Sides, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
State Of Missouri	MO	Rehabilitation Counselor	$0	$160.2M
Help At Home, LLC	MO	Intellectual and/or Developmental Disabilities Community Based Residential Treatment Facility	$0	$97M
Ssm Regional Health Services	MO	General Acute Care Hospital	$0	$20.8M
Rehab Specialty Medical, Inc.	MO	Intellectual and/or Developmental Disabilities Community Based Residential Treatment Facility	$0	$19.7M
Day Solutions, Inc	MO	Intellectual and/or Developmental Disabilities Community Based Residential Treatment Facility	$0	$14M
Skillset LLC	MO	Intellectual and/or Developmental Disabilities Community Based Residential Treatment Facility	$0	$11.6M
Independent Living Resource Center, Inc.	MO	Home Health Agency	$0	$8.3M
Tiffany Burns	MO	Student in an Organized Health Care Education/Training Program	$0	$7.7M
County Of Cole	MO	Land Ambulance	$809.3K	$5.2M
Community Hospices Of America, LLC	MO	Community Based Hospice Care Agency	$0	$4M

Stephen Sides — Billing Profile & Reimbursement Data

Sign up for Stephen Sides — Billing Profile & Reimbursement Data policy alerts

Stephen Sides — Billing Profile & Reimbursement Data

Sign up for Stephen Sides — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References